Handelsbanken Fonder AB Has $820,000 Stock Holdings in Azenta, Inc. (NASDAQ:AZTA)

Handelsbanken Fonder AB decreased its stake in Azenta, Inc. (NASDAQ:AZTA) by 12.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,581 shares of the company’s stock after selling 1,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Azenta were worth $820,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in shares of Azenta by 0.8% in the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 4,531,739 shares of the company’s stock worth $227,448,000 after buying an additional 38,116 shares during the period. Conestoga Capital Advisors LLC boosted its stake in Azenta by 13.4% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,291,284 shares of the company’s stock worth $84,114,000 after purchasing an additional 152,090 shares during the period. Teacher Retirement System of Texas grew its position in Azenta by 78.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 1,147,753 shares of the company’s stock worth $57,606,000 after purchasing an additional 505,412 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in Azenta by 32.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 538,566 shares of the company’s stock valued at $27,031,000 after purchasing an additional 133,463 shares during the period. Finally, Rock Springs Capital Management LP lifted its holdings in shares of Azenta by 1.6% in the third quarter. Rock Springs Capital Management LP now owns 477,500 shares of the company’s stock valued at $23,966,000 after purchasing an additional 7,600 shares in the last quarter. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Azenta Stock Up 2.0 %

NASDAQ AZTA opened at $53.21 on Tuesday. The company has a 50 day moving average price of $59.16 and a two-hundred day moving average price of $59.12. Azenta, Inc. has a 12-month low of $36.01 and a 12-month high of $69.16. The stock has a market capitalization of $2.97 billion, a PE ratio of -171.64 and a beta of 1.53.

Azenta (NASDAQ:AZTA) last released its quarterly earnings data on Wednesday, February 7th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $154.32 million during the quarter, compared to analyst estimates of $151.86 million. Azenta had a negative net margin of 2.92% and a positive return on equity of 0.49%. As a group, equities analysts anticipate that Azenta, Inc. will post 0.27 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Evercore ISI dropped their price target on Azenta from $64.00 to $60.00 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Azenta in a report on Monday, April 8th. Jefferies Financial Group started coverage on shares of Azenta in a report on Thursday, April 4th. They set a “hold” rating and a $64.00 price target for the company. Stephens reiterated an “equal weight” rating and issued a $70.00 price objective on shares of Azenta in a research note on Thursday, February 8th. Finally, B. Riley boosted their price target on shares of Azenta from $61.00 to $79.00 and gave the company a “buy” rating in a report on Thursday, February 1st. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $69.60.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.